CompletedNCT02524899
Guanfacine Added to Cognitive Remediation for Schizotypal Personality
About this title
Read the official source — NCT02524899Medication studyAges 18–65United StatesPersonality disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJanuary 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 45
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University
- Study type
- Behavioral
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02524899
- Official title
Show the full official title
Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Registry details
Registry conditions (original wording)
Schizotypal Personality Disorder; SPD
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Icahn School of Medicine at Mount Sinai, a university.
Did this study involve medication?
Yes. The study involved medication, including Guanfacine and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
